Mar 30, 2023: Introducing BADBIR, a UK psoriasis registry

The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a national register of all patients receiving biologic therapy for the treatment of psoriasis in the United Kingdom. The National Institute for Health and Clinical Excellence (NICE) has recommended that all patients in the UK receiving these new therapies for Psoriasis should be registered in BADBIR. BADBIR has grown to be the largest psoriasis study of its kind globally.

British Association of Dermatologists Biologic Interventions Register (BADBIR) (United Kingdom) **

Database Contact Data

BADBIR
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester M15 6GZ
UNITED KINGDOM
Main Office Phone: +44 0161 306 1896
Email: badbir@manchester.ac.uk

Alternate Contact

Ian Evans
Manager
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester M15 6GZ
UNITED KINGDOM
Email: Ian.Evans@manchester.ac.uk

References of Studies Using/Describing Database

1. Yiu ZZ, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CE, Browne F, Evans I, Kleyn E. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA dermatology. 2022 Oct 1;158(10):1131-41.

2. Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis. J Invest Dermatol. 2022 Jun;142(6):1617-1628.e10.

3. Jalali-Najafabadi F, Stadler M, Dand N, Jadon D, Soomro M, Ho P, Marzo-Ortega H, Helliwell P, Korendowych E, Simpson MA, Packham J. Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. Scientific reports. 2021 Dec 2;11(1):1-4.

4. Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN, Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium. Defining trajectories of response in patients with psoriasis treated with biologic therapies. Br J Dermatol. 2021 Oct;185(4):825-835.

5. Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD; BADBIR Study Group. Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e496-e498.

6. Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD; BADBIR Study Group. Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e498-e501.

7. Yiu ZZ, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CE, Warren RB, BADBIR Study Group. Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA dermatology. 2021 Jan 1;157(1):66-73.

8. Yiu ZZ, Mason KJ, Smith CH, Griffiths CE, BADBIR Study Group. The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. British Journal of Dermatology. 2020 Dec;183(6):981-3.

9. Yiu ZZ, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CE, Warren RB, BADBIR Study Group. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2020 Aug;183(2):294-302.

10. Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CE, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN. Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). British Journal of Dermatology. 2020 May;182(5):1158-66.

Mar 22, 2023: Why are some databases not currently profiled on B.R.I.D.G.E. TO DATA®?

The main goal of B.R.I.D.G.E. is to profile databases from around the world with the most current information. Therefore, B.R.I.D.G.E. profiles databases as new ones are created. We usually work with each database manager to ensure their database profile is complete and accurate. Although we try to include as many profiles on our web site as possible, we unfortunately cannot profile every database.

Mar 14, 2023: Read about our 8th healthcare database profile from Estonia

Established in January 2015, the Estonian Cancer Screening Register records data on the 3 available population-based cancer screenings in Estonia: breast, cervical and colorectal cancer. While the breast cancer screening started in 2003, and the cervical cancer screening in 2006, the data have been added to ECSR only since 2015, while colorectal cancer screening data in Estonia were added to the register in 2016.

National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) (United Kingdom)

Database Contact Data

For requests for data which sit under the National Congenital Anomaly and Rare Diseases Registration Service (NCARDRS) suite of products, please email ndrsenquiries@nhs.net.

To discuss any aspect of DARS or an existing application call the team on +44 (0)300 303 5678 or email enquiries@nhsdigital.nhs.uk.

Alternate Contact

Danielle Martin
National Senior Data Analyst 
National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) 
Public Health England
Wellington House
133-155 Waterloo Road
London, England SE1 8UG
UNITED KINGDOM
Email: danielle.martin@phe.gov.uk  
Phone: +44 (0)191 242 6003
Mobile: +44 (0) 7554111236

References of Studies Using/Describing Database

1. Odingo M, Rutter M, Bowley J, Peach EJ, Lanyon PC, Grainge MJ, Stillwell P, McPhail S, Bythell M, Aston J, Stevens S. The incidence of Kawasaki disease using hospital admissions data for England 2006–2021. Rheumatology. 2023 Jan 30:kead051.

2. Moss C, Roked F, Davis PJ, Khan M, Tyler C, Ibbs S, Ewer AK. Birth incidence and outcome of harlequin ichthyosis and collodion membrane in the UK and Ireland: a national 2-year prospective surveillance study. British Journal of Dermatology. 2023 Jan;188(1):139-40.

3. Aldridge N, Pandya P, Rankin J, Miller N, Broughan J, Permalloo N, McHugh A, Stevens S. Detection rates of a national fetal anomaly screening programme: A national cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2023 Jan;130(1):51-8.

4. Aslam AA, Baksh RA, Pape SE, Strydom A, Gulliford MC, Chan LF, Go-DS21 Consortium, Herault Yann Strydom Andre Chan Li Potier Marie-Claude Beckers Johannes Liò Pietro Dierssen Mara. Diabetes and obesity in Down Syndrome across the lifespan: a retrospective cohort study using UK electronic health records. Diabetes care. 2022 Dec;45(12):2892-9.

5. West J, Stilwell P, Liu H, Ban L, Bythell M, Card T, Lanyon P, Nanduri V, Rankin J, Bishton M, Crooks C. Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England. Blood. 2022 Nov 15;140(Supplement 1):5469-70.

6. Bishton M, Crooks C, Liu H, Ban L, Bythell M, Card T, Lanyon P, Nanduri V, Rankin J, Stilwell P, West J. Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors. Blood. 2022 Nov 15;140(Supplement 1):2599-600.

7. Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Peach E, Bythell M, Stilwell P, Aston J, Stevens S, Pearce FA. COVID-19 infection, admission and death among people with rare autoimmune rheumatic disease in England: results from the RECORDER project. Rheumatology. 2022 Aug;61(8):3161-71.

8. Hill M, Ellard S, Fisher J, Fulop N, Knight M, Kroese M, Ledger J, Leeson-Beevers K, McEwan A, McMullan D, Mellis R. Optimising Exome Prenatal Sequencing Services (EXPRESS): a study protocol to evaluate rapid prenatal exome sequencing in the NHS Genomic Medicine Service [version 2; peer review: 2 approved]. NIHR open research. 2022 Jul 18;2:10.

9. Murray CS, Walsh T, Bannister T, Metryka A, Davies K, Lin YL, Williamson P, Callery P, O’Brien K, Shaw W, Bruce I. Does Sleep Position Influence Sleep-Disordered Breathing in Infants With Cleft Palate: A Feasibility Study?. The Cleft Palate-Craniofacial Journal. 2022 Feb;59(2):254-61.

10. Hannah JR, Gordon PA, Galloway J, Rutter M, Peach EJ, Rooney M, Stilwell P, Grainge MJ, Lanyon PC, Bythell M, Pearce FA. Validation of methods to identify people with idiopathic inflammatory myopathies using hospital episode statistics. Rheumatology Advances in Practice. 2022;6(3):rkac102.

Subscribe to